MedTrace Logo

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2011-09-27

No results posted yet for this study

Summary

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

R89674 (generic name not yet established)

Sponsors & Collaborators

  • Vistakon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ingerman Avner, MD · Johnson & Johnson

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244543 on ClinicalTrials.gov